Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study

Mathias Jachs(Medical University of Vienna), Péter Ferenci(Medical University of Vienna), Stephan W. Aberle(Medical University of Vienna), Marlene Panzer(Innsbruck Medical University), Caroline Schwarz(Otto Wagner Hospital), Heidemarie Holzmann(Medical University of Vienna), Lukas Hartl(Medical University of Vienna), K Dax(Kepler Universitätsklinikum), Michael Gschwantler(European Society of Radiology), Teresa Binter(Medical University of Vienna), Petra Munda(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), Albert Friedrich Stättermayer(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Heinz Zoller(Universität Innsbruck), Elmar Aigner, Ivo Graziadei(Landeskrankenhaus Feldkirch), Mattias Mandorfer(Medical University of Vienna)
Alimentary Pharmacology & Therapeutics
May 5, 2022
10.1111/apt.16945
Cited by 73

Related Papers

Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
|Hepatology|2014|2k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline
|Endoscopy|2017|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
ESPEN Guidelines on Enteral Nutrition: Liver disease
|Clinical Nutrition|2006|683